Categories: HealthcareNews

DuPont Schedules Third Quarter 2025 Earnings Conference Call

WILMINGTON, Del., Oct. 20, 2025 /PRNewswire/ — DuPont (NYSE: DD) will release its third quarter financial results at 6:00 a.m. ET on Thursday, November 6, 2025. In addition, the company will host a conference call at 8:00 a.m. ET that day.

The event will be webcast live and can be accessed on DuPont’s Investors Relations webpage. A replay, along with the earnings release and supporting materials, will also be posted to the website.

The dial-in number for the conference call is 888-440-4172 toll-free within the U.S. or +1-646-960-0673. The conference ID is 5994046.

DuPont will reflect the previously announced divestiture of its Aramids business as discontinued operations beginning with third quarter 2025 reporting and will reflect its electronics business, Qnity, as discontinued operations beginning in fourth quarter 2025 reporting following the intended separation of Qnity on November 1, 2025.

Qnity expects to provide a business update on a separate conference call to be announced at a later date.

About DuPont
DuPont (NYSE: DD) is a global innovation leader with technology-based materials and solutions that help transform industries and everyday life. Our employees apply diverse science and expertise to help customers advance their best ideas and deliver essential innovations in key markets including electronics, transportation, construction, water, healthcare and worker safety. More information about the company, its businesses and solutions can be found at www.dupont.com. Investors can access information included on the Investor Relations section of the website at investors.dupont.com.

DuPontTM and all products, unless otherwise noted, denoted with TM, SMor ® are trademarks, service marks or registered trademarks of affiliates of DuPont de Nemours, Inc.

View original content to download multimedia:https://www.prnewswire.com/news-releases/dupont-schedules-third-quarter-2025-earnings-conference-call-302587880.html

SOURCE DuPont

Staff

Recent Posts

Cue Biopharma Announces Pricing of $10 Million Public Offering

BOSTON, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical…

7 seconds ago

IN8bio Announces Pricing of Private Placement of up to $40.2 Million to Advance Novel Gamma-Delta T Cell Engager

$20.1 million upfront with a milestone-driven additional $20.1 million to advance INB-619, IN8bio’s novel gamma-delta…

14 seconds ago

NeurAxis Achieves Medical Coverage Policy Milestone, Expanding Access to Approximately 45 million additional Covered Lives

Total national coverage footprint for PENFS increases to roughly 100 million covered livesCARMEL, Ind., Dec.…

23 seconds ago

Glass House Brands Applauds Cannabis Reform Action

LONG BEACH, Calif. and TORONTO, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Glass House Brands Inc.…

25 seconds ago

Mangoceuticals, Inc. Announces Partnership with The Cube Group to Launch Up To $100 Million Solana-Focused Digital Asset Treasury (DAT) Strategy

MULTI-DAT Framework Drives Diversified Crypto Expansion and Volatility Hedging DALLAS, TX, Dec. 19, 2025 (GLOBE…

28 seconds ago

Avicanna Applauds President Trump’s Executive Order to Reclassify Cannabis & Provides Scientific Update

Avicanna’s evidence-based pathway for cannabinoid-based medicine aligns with the executive order. Avicanna’s 2025 advances across…

36 seconds ago